To the full analysis
Globus Medical stock: valuation and P/E
GMEDGlobus Medical trades at a P/E of 17.6 (Medical (Devices) median 29.1, own median of recent years 38.4).
Daily figure as of 13 Nov 2026
P/E
17.6
P/S
3.1
P/B
2.05
PEG
2.05
P/E on expected earnings
The forward P/E of 13.5 divides the price by the earnings per share that 8 analysts expect on average for the next twelve months: $5.34. The twelve months are made up pro rata of the estimates for fiscal 2026 and 2027.
13.5
P/E on fiscal 2026
14.5
on estimated fiscal 2026 earnings ($5.00 per share)
P/E on fiscal 2027
13.4
on estimated fiscal 2027 earnings ($5.39 per share)
Analysts mostly estimate adjusted earnings, excluding amortization of acquisitions and other one-off items. The estimates change all the time; they are no promise and no price target.
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
P/E
17.6
Median of prior years
38.4
Reading
cheaper than usual
P/E at each fiscal year end
Figures as a table
| Year | P/E |
|---|---|
| 2016 | 22.8 |
| 2017 | 36.7 |
| 2018 | 27.1 |
| 2019 | 37.5 |
| 2020 | 62.7 |
| 2021 | 48.8 |
| 2022 | 39.3 |
| 2023 | 48.9 |
| 2024 | 108.8 |
| 2025 | 21.9 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.